263 related articles for article (PubMed ID: 8289379)
1. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
[TBL] [Abstract][Full Text] [Related]
2. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
Eberle J; Bechowsky B; Rose D; Hauser U; von der Helm K; Gürtler L; Nitschko H
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):671-6. PubMed ID: 7576926
[TBL] [Abstract][Full Text] [Related]
3. Detection of southern African human immunodeficiency virus type 1 subtypes by polymerase chain reaction: evaluation of different primer pairs and conditions.
Engelbrecht S; van Rensburg EJ
J Virol Methods; 1995 Nov; 55(3):391-400. PubMed ID: 8609204
[TBL] [Abstract][Full Text] [Related]
4. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
[TBL] [Abstract][Full Text] [Related]
5. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
Jacobsen H; Ahlborn-Laake L; Gugel R; Mous J
J Virol; 1992 Aug; 66(8):5087-91. PubMed ID: 1378515
[TBL] [Abstract][Full Text] [Related]
6. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E
J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548
[TBL] [Abstract][Full Text] [Related]
7. HIV proteinase inhibitors.
Roberts NA; Craig JC; Duncan IB
Biochem Soc Trans; 1992 May; 20(2):513-6. PubMed ID: 1397651
[No Abstract] [Full Text] [Related]
8. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Uchida H; Maeda Y; Mitsuya H
Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
[TBL] [Abstract][Full Text] [Related]
10. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
Johnson VA; Merrill DP; Chou TC; Hirsch MS
J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type 1 infection requires reverse transcription of nascent viral RNA.
Potash MJ; Li G; Shahabuddin M; Pellegrino MG; Volsky DJ
DNA Cell Biol; 1993 Oct; 12(8):685-93. PubMed ID: 7691074
[TBL] [Abstract][Full Text] [Related]
13. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
[TBL] [Abstract][Full Text] [Related]
14. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.
Ojwang JO; Buckheit RW; Pommier Y; Mazumder A; De Vreese K; Esté JA; Reymen D; Pallansch LA; Lackman-Smith C; Wallace TL
Antimicrob Agents Chemother; 1995 Nov; 39(11):2426-35. PubMed ID: 8585721
[TBL] [Abstract][Full Text] [Related]
15. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
Jacobsen H; Yasargil K; Winslow DL; Craig JC; Kröhn A; Duncan IB; Mous J
Virology; 1995 Jan; 206(1):527-34. PubMed ID: 7831807
[TBL] [Abstract][Full Text] [Related]
16. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells.
Pettit SC; Sanchez R; Smith T; Wehbie R; Derse D; Swanstrom R
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):1007-14. PubMed ID: 9686647
[TBL] [Abstract][Full Text] [Related]
17. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
[TBL] [Abstract][Full Text] [Related]
18. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J
J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209
[TBL] [Abstract][Full Text] [Related]
19. Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences.
Gorelick RJ; Gagliardi TD; Bosche WJ; Wiltrout TA; Coren LV; Chabot DJ; Lifson JD; Henderson LE; Arthur LO
Virology; 1999 Mar; 256(1):92-104. PubMed ID: 10087230
[TBL] [Abstract][Full Text] [Related]
20. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
Lamarre D; Croteau G; Wardrop E; Bourgon L; Thibeault D; Clouette C; Vaillancourt M; Cohen E; Pargellis C; Yoakim C; Anderson PC
Antimicrob Agents Chemother; 1997 May; 41(5):965-71. PubMed ID: 9145853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
